NASDAQ: PBLSParabilis Medicines Inc Stock
$38.76-1.01 (-2.54%)
Updated Sep 9, 2026
PBLS Price
$38.76
Fair Value Price
-$15.32
Market Cap
$4.79B
52 Week Low
$24.66
52 Week High
$41.49
P/E
N/A
P/B
4.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
N/A
Beta
-0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PBLS Overview
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PBLS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PBLS
Ranked#169 of 461
Ranked#169 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.05 | A | |
| $115.70 | A | |
| $6.80 | A |
Be the first to know about important PBLS news, forecast changes, insider trades & much more!
PBLS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PBLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PBLS ($38.76) is overvalued by 353.05% relative to our estimate of its Fair Value price of -$15.32 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PBLS ($38.76) is not significantly undervalued (353.05%) relative to our estimate of its Fair Value price of -$15.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PBLS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PBLS due diligence checks available for Premium users.
Valuation
PBLS fair value
Fair Value of PBLS stock based on Discounted Cash Flow (DCF)
Price
$38.76
Fair Value
-$15.32
Undervalued by
353.05%
PBLS ($38.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PBLS ($38.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PBLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.57x
Industry
5.42x
PBLS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PBLS's financial health
Profit margin
Revenue
$148.0k
Net Income
-$52.5M
Profit Margin
-45,239.9%
Assets to liabilities
Assets
$1.2B
Liabilities
$127.5M
Debt to equity
0.12
PBLS's short-term assets ($1.13B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PBLS's short-term assets ($1.13B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PBLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
-$34.1M
Financing
$795.7M
PBLS vs Biotech Stocks
Parabilis Medicines Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.